Concurrent Activation of Both Survival-Promoting and Death-Inducing Signaling by Chloroquine in Glioblastoma Stem Cells: Implications for Potential Risks and Benefits of Using Chloroquine as Radiosensitizer.
AKT
ATM
HIPK2
chloroquine
glioblastoma radiosensitization
glioblastoma stem cells
p21-DREAM
p53
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
30 04 2023
30 04 2023
Historique:
received:
26
03
2023
revised:
25
04
2023
accepted:
27
04
2023
medline:
15
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
Lysosomotropic agent chloroquine was shown to sensitize non-stem glioblastoma cells to radiation in vitro with p53-dependent apoptosis implicated as one of the underlying mechanisms. The in vivo outcomes of chloroquine or its effects on glioblastoma stem cells have not been previously addressed. This study undertakes a combinatorial approach encompassing in vitro, in vivo and in silico investigations to address the relationship between chloroquine-mediated radiosensitization and p53 status in glioblastoma stem cells. Our findings reveal that chloroquine elicits antagonistic impacts on signaling pathways involved in the regulation of cell fate via both transcription-dependent and transcription-independent mechanisms. Evidence is provided that transcriptional impacts of chloroquine are primarily determined by p53 with chloroquine-mediated activation of pro-survival mevalonate and p21-DREAM pathways being the dominant response in the background of wild type p53. Non-transcriptional effects of chloroquine are conserved and converge on key cell fate regulators ATM, HIPK2 and AKT in glioblastoma stem cells irrespective of their p53 status. Our findings indicate that pro-survival responses elicited by chloroquine predominate in the context of wild type p53 and are diminished in cells with transcriptionally impaired p53. We conclude that p53 is an important determinant of the balance between pro-survival and pro-death impacts of chloroquine and propose that p53 functional status should be taken into consideration when evaluating the efficacy of glioblastoma radiosensitization by chloroquine.
Identifiants
pubmed: 37174691
pii: cells12091290
doi: 10.3390/cells12091290
pmc: PMC10177603
pii:
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Chloroquine
886U3H6UFF
Radiation-Sensitizing Agents
0
HIPK2 protein, human
EC 2.7.1.-
Carrier Proteins
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Mol Cancer Ther. 2018 Feb;17(2):336-346
pubmed: 28838997
Nature. 2003 Jan 30;421(6922):499-506
pubmed: 12556884
PLoS One. 2015 Jun 18;10(6):e0130519
pubmed: 26086074
Oncogene. 2014 Sep 18;33(38):4685-96
pubmed: 24121268
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
J Neuropathol Exp Neurol. 2013 Apr;72(4):307-24
pubmed: 23481707
Genes Dev. 2001 May 1;15(9):1067-77
pubmed: 11331603
Ann Intern Med. 2006 Mar 7;144(5):337-43
pubmed: 16520474
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Cell Death Differ. 2022 May;29(5):946-960
pubmed: 35361964
Free Radic Biol Med. 2016 Jan;90:91-100
pubmed: 26577174
Nat Rev Cancer. 2016 Nov;16(11):718-731
pubmed: 27562463
Nat Rev Mol Cell Biol. 2015 Jul;16(7):393-405
pubmed: 26122615
Bioessays. 2019 Dec;41(12):e1900127
pubmed: 31621101
Cancer Res. 2019 Aug 15;79(16):4057-4071
pubmed: 31292163
Nat Rev Drug Discov. 2020 Jan;19(1):23-38
pubmed: 31712683
Bioinformatics. 2004 Feb 12;20(3):307-15
pubmed: 14960456
Neuro Oncol. 2014 Oct;16(10):1313-23
pubmed: 24811392
Cancer Lett. 2015 May 1;360(2):195-204
pubmed: 25681668
Cell Div. 2020 Feb 27;15:4
pubmed: 32127912
Cancers (Basel). 2020 Sep 03;12(9):
pubmed: 32899427
Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):182-7
pubmed: 26677873
Cell Death Dis. 2020 Dec 4;11(12):1034
pubmed: 33277461
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
J Biol Chem. 2007 Jul 20;282(29):21206-12
pubmed: 17513297
Signal Transduct Target Ther. 2017 Sep 29;2:17040
pubmed: 29263927
Br J Cancer. 2019 Mar;120(5):481-487
pubmed: 30745581
Oncogene. 2015 Oct 1;34(40):5128-40
pubmed: 25619842
Front Genet. 2022 Mar 22;13:841639
pubmed: 35391801
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Oncol Lett. 2020 Sep;20(3):2356-2368
pubmed: 32782553
CNS Neurosci Ther. 2022 Jan;28(1):158-171
pubmed: 34697897
Front Oncol. 2018 Aug 27;8:335
pubmed: 30211116
Bioinformatics. 2004 Dec 12;20(18):3705-6
pubmed: 15297296
PLoS Biol. 2010 Feb 23;8(2):e1000319
pubmed: 20186265
Cell Rep. 2017 Jan 10;18(2):508-519
pubmed: 28076793
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
J Neurooncol. 2001 Jun;53(2):161-76
pubmed: 11716068
Biochem Biophys Res Commun. 2018 Jun 7;500(3):569-576
pubmed: 29655792
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3421-6
pubmed: 25737557
J Hematol Oncol. 2021 Sep 28;14(1):157
pubmed: 34583722
Nat Rev Mol Cell Biol. 2013 Apr;14(4):197-210
pubmed: 23847781
BMC Neurol. 2016 Sep 20;16(1):178
pubmed: 27644442
J Cell Physiol. 2022 Jan;237(1):313-328
pubmed: 34515349
Autophagy. 2012 Feb 1;8(2):200-12
pubmed: 22252008
Strahlenther Onkol. 2014 Oct;190(10):957-61
pubmed: 24928248
Neuro Oncol. 2010 Apr;12(4):389-400
pubmed: 20308316
Cancers (Basel). 2020 Feb 24;12(2):
pubmed: 32102350
EMBO J. 2009 Dec 16;28(24):3857-67
pubmed: 19816404
Nat Commun. 2022 May 19;13(1):2800
pubmed: 35589715
Eur J Pharmacol. 2016 Jan 15;771:139-44
pubmed: 26687632
Genome Biol. 2004;5(10):R80
pubmed: 15461798
Neuro Oncol. 2010 May;12(5):473-81
pubmed: 20406898
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
Bioessays. 2013 Jan;35(1):55-64
pubmed: 23169233
Am J Pathol. 2010 Oct;177(4):1618-28
pubmed: 20813964
Front Oncol. 2021 May 25;11:668090
pubmed: 34211843
Nat Cell Biol. 2002 Jan;4(1):1-10
pubmed: 11740489
Neurosurg Focus. 2014 Dec;37(6):E12
pubmed: 25434381
Autophagy. 2021 Sep;17(9):2604-2612
pubmed: 32866424
Mol Ther. 2014 Aug;22(8):1407-1415
pubmed: 24827908
Cancer Biol Ther. 2009 Apr;8(8):730-8
pubmed: 19252415
Front Oncol. 2020 Nov 20;10:590861
pubmed: 33330074
Mol Cancer Res. 2015 Jan;13(1):16-28
pubmed: 25158956
Oncogene. 2016 Aug 25;35(34):4518-28
pubmed: 26853465
Cell Death Differ. 2016 Jan;23(1):110-22
pubmed: 26113041
Cell Rep. 2016 Sep 6;16(10):2618-2629
pubmed: 27568562
Anticancer Res. 2005 Jan-Feb;25(1A):213-24
pubmed: 15816541
Genes Dev. 2019 Jun 1;33(11-12):591-609
pubmed: 31160393
Front Oncol. 2020 Jul 17;10:1138
pubmed: 32766148
Oncotarget. 2017 Oct 11;8(59):100931-100941
pubmed: 29246031
Nucleic Acids Res. 2016 Jul 27;44(13):6070-86
pubmed: 27280975
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Cell Death Differ. 2018 Jan;25(1):114-132
pubmed: 29125603
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):
pubmed: 27836911
J Clin Invest. 2017 Feb 1;127(2):415-426
pubmed: 28145904
Exp Cell Res. 2022 Jan 1;410(1):112949
pubmed: 34843714
Cell Death Differ. 2019 Jan;26(2):199-212
pubmed: 30538286
Neurosurg Focus. 2003 Feb 15;14(2):e3
pubmed: 15727424
Clin Transl Oncol. 2016 Nov;18(11):1062-1071
pubmed: 26960561
Neuropathol Appl Neurobiol. 2012 Apr;38(2):201-12
pubmed: 21722156
Cancer Drug Resist. 2020 Aug 07;3(3):287-301
pubmed: 35582442
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
J Cell Biol. 2008 Oct 6;183(1):101-16
pubmed: 18838554
Nat Rev Clin Oncol. 2018 Jan;15(1):13-30
pubmed: 28948977
Cell Death Dis. 2022 Apr 1;13(4):293
pubmed: 35365623
Cancers (Basel). 2020 Mar 01;12(3):
pubmed: 32121554
Gene. 2022 May 25;824:146395
pubmed: 35283227
Am J Physiol Renal Physiol. 2006 Dec;291(6):F1300-7
pubmed: 16849690
Sci Rep. 2016 Mar 11;6:22921
pubmed: 26964637
Pharmacol Rev. 2018 Jul;70(3):412-445
pubmed: 29669750
Free Radic Biol Med. 2017 Mar;104:280-297
pubmed: 28131902
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Biomedicines. 2021 Dec 22;10(1):
pubmed: 35052687